Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors. Friday, shares are trading lower after several analysts downgraded the stock after the company released the data. Needham…#phase1 #imm1104 #ras #imm1104sphase #nras #needham #pfizerincs #pfemektovi #pdac #tdcowen
Source: Reuters: Health - Category: Consumer Health News Source Type: news